Forte Biosciences, Inc.

NasdaqCM FBRX

Forte Biosciences, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 1,747,402

Forte Biosciences, Inc. Shares (Diluted, Weighted) is 1,747,402 for the Trailing 12 Months (TTM) ending September 30, 2024, a 73.15% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Forte Biosciences, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 1,009,163, a 59.67% change year over year.
Forte Biosciences, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 632,029, a 17.20% change year over year.
Forte Biosciences, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 539,278, a 198.83% change year over year.
Forte Biosciences, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 180,462.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: FBRX

Forte Biosciences, Inc.

CEO	Dr. Paul A. Wagner Ph.D.
IPO Date	April 13, 2017
Location	United States
Headquarters	3060 Pegasus Park Drive
Employees	11
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Key trends

Past 5 years